Major Step Forward for Lung Cancer Research & Early Detection
The FY2026 federal budget marks a meaningful milestone for the lung cancer community—one that reflects years of advocacy, collaboration, and persistence from patients, caregivers, researchers, and champions across the country.
What the Lung Cancer Research Program Funding Supports
The Lung Cancer Research Program, housed within the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP), is designed to fund innovative, high-impact research that may not yet be supported through traditional funding mechanisms.
Importantly, the LCRP requires that consumer advocates—patients and survivors—are involved in the research review process, ensuring funded projects remain grounded in real-world needs and lived experience.
This investment helps fuel innovation while addressing gaps that have historically slowed progress in lung cancer research.
Expanding Access to Multi-Cancer Early Detection
In addition to research funding, the passage of bipartisan legislation (H.R. 842 and S. 339) paves the way for Medicare coverage of FDA-approved multi-cancer early detection tests.
The legislation allows Medicare to cover blood-based screening tests intended to:
- Detect multiple cancers at earlier stages
- Be used alongside—not in place of—existing, evidence-based cancer screenings
- Improve early diagnosis for cancers that currently lack routine screening options
Earlier detection saves lives. By expanding coverage, this legislation helps reduce financial barriers and brings promising innovation closer to the people who need it most.
Why This Matters
In addition to research funding, the passage of bipartisan legislation (H.R. 842 and S. 339) paves the way for Medicare coverage of FDA-approved multi-cancer early detection tests.
Lung cancer remains the leading cause of cancer death, in large part because it is often diagnosed too late. These federal actions directly support:
- Innovation through sustained research investment
- Early detection that can change outcomes
- Equitable access to emerging technologies
- Collaboration across sectors to accelerate progress
They also reinforce an essential truth: progress happens when patients, advocates, researchers, and policymakers work together.
The Work Continues
While these victories are significant, they are not the finish line. Continued advocacy is needed to ensure funding keeps pace with scientific opportunity, screening access expands, and all communities—especially rural and underserved populations—benefit from advances in lung cancer care.
